Signals
One Blood Test for 50 Cancers Is Closer to the FDA. The Evidence Is Still Fighting Back.
An FDA advisory panel has backed GRAIL’s Galleri multi-cancer blood test for adults aged 50 and older. The vote could open a new era in cancer screening. It also exposes how unsettled the evidence remains over what “early detection” should actually prove.
Obesity drugs may move beyond appetite suppression. Moonwalk just raised $70 million to target fat tissue directly
Novartis lowered Lp(a) but not cardiovascular risk. What went wrong?
Gestational diabetes is not over at delivery. Postpartum care may be missing the real cardiometabolic warning
Beyond GLP-1s: Lilly is spending billions on a more targeted future in neuroscience
Breastfeeding Enters the MOGAD Conversation
More than half had silent atherosclerosis. Standard risk scores missed many of them
AstraZeneca’s Wainua lowered a disease-causing protein but did not reduce heart complications in a major trial
FDA Is Asking the Right AI Question: Who Watches the Model After Approval?
The same weight loss produced different metabolic benefits. Diet quality may matter as much as kilograms lost
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.